Vol 14, No 1 (2011)
Research paper
Published online: 2011-07-12
The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves’ disease and toxic nodular goitre
Nucl. Med. Rev 2011;14(1):9-15.
Abstract
BACKGROUND: The aim of the study was to achieve an effective
target dose in the thyroid by increasing the effective half-life
(Teff) of 131I by use of iodide (127I) two days after 131I therapy in
patients with hyperthyroidism with low Teff.
MATERIAL AND METHODS: The study was carried out in two groups. Group A — 41 patients, and Group B — 14 patients, all the patients were with hyperthyroidism with Teff less than 3 days qualified for 131I therapy. Only group A patients received 600 μg of iodide a day for 3 days, two days after 131I therapy. Radioiodine uptake (RAIU) after 24 and 48 hours, thyroid scintiscan and ultrasonography were done before and after 12 months of 131I therapy.
RESULTS: In group A a significant increase was seen in the Teff (5 days on average) resulting in an increase in the energy target dose by 28% and 37%, in patients with Graves’ disease (GD) and toxic nodular goitre (TNG), respectively. After one year of therapy 50% of GD and 93% of TNG patients achieved euthyroidism; 28% of GD and 3% of TNG patients were in hypothyroidism. In Group B, all the patients had radioiodine treatment failure and received a second therapeutic dose of 131I.
CONCLUSIONS: Administration of 127I after 131I treatment can lead to an increase in its effective half-life. This will also increase the absorbed energy dose in thyroid tissue, thereby improving therapeutic outcome without administration of a higher or second dose of 131I. This may minimize whole-body exposure to radiation and reduces the cost of treatment.
Nuclear Med Rev 2011; 14, 1: 9–15
MATERIAL AND METHODS: The study was carried out in two groups. Group A — 41 patients, and Group B — 14 patients, all the patients were with hyperthyroidism with Teff less than 3 days qualified for 131I therapy. Only group A patients received 600 μg of iodide a day for 3 days, two days after 131I therapy. Radioiodine uptake (RAIU) after 24 and 48 hours, thyroid scintiscan and ultrasonography were done before and after 12 months of 131I therapy.
RESULTS: In group A a significant increase was seen in the Teff (5 days on average) resulting in an increase in the energy target dose by 28% and 37%, in patients with Graves’ disease (GD) and toxic nodular goitre (TNG), respectively. After one year of therapy 50% of GD and 93% of TNG patients achieved euthyroidism; 28% of GD and 3% of TNG patients were in hypothyroidism. In Group B, all the patients had radioiodine treatment failure and received a second therapeutic dose of 131I.
CONCLUSIONS: Administration of 127I after 131I treatment can lead to an increase in its effective half-life. This will also increase the absorbed energy dose in thyroid tissue, thereby improving therapeutic outcome without administration of a higher or second dose of 131I. This may minimize whole-body exposure to radiation and reduces the cost of treatment.
Nuclear Med Rev 2011; 14, 1: 9–15
Keywords: non-radioactive iodine-127toxic nodular goitreGraves’ diseaseradioiodine therapy
